圣湘生物
(688289)
| 流通市值：127.29亿 | | | 总市值：127.29亿 |
| 流通股本：5.79亿 | | | 总股本：5.79亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,244,138,989.62 | 868,620,485.26 | 475,488,325.65 | 1,458,061,552.96 |
| 营业收入 | 1,244,138,989.62 | 868,620,485.26 | 475,488,325.65 | 1,458,061,552.96 |
| 二、营业总成本 | 1,066,909,188.78 | 702,919,097.81 | 360,282,099.93 | 1,278,340,817.64 |
| 营业成本 | 336,216,232.56 | 232,065,994.95 | 110,726,245.56 | 322,054,954.12 |
| 税金及附加 | 8,268,826.66 | 5,360,228.15 | 2,842,427.76 | 12,412,479.1 |
| 销售费用 | 422,305,101.98 | 276,486,681.39 | 148,902,887.06 | 499,820,112.75 |
| 管理费用 | 170,598,896.59 | 104,996,177.22 | 58,460,314.53 | 251,654,185.67 |
| 研发费用 | 178,841,044.52 | 118,560,953.24 | 59,028,378.14 | 277,685,929.66 |
| 财务费用 | -49,320,913.53 | -34,550,937.14 | -19,678,153.12 | -85,286,843.66 |
| 其中:利息费用 | 17,569,902.1 | 11,439,504.39 | 6,099,989.74 | 18,395,334.85 |
| 其中:利息收入 | 65,576,635.78 | 45,280,372.46 | 23,197,918.99 | 97,526,509.16 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 47,982,843.43 | 47,493,750.56 | 1,147,650.07 | 8,408,087.48 |
| 加:投资收益 | -38,755,321.07 | -24,953,300.33 | -13,365,546.27 | -28,844,174.11 |
| 资产处置收益 | -4,351,330.5 | -3,044,178.72 | 258,365.08 | -2,362,321.35 |
| 资产减值损失(新) | 10,778,890.25 | 8,604,506.41 | 895,902.96 | 43,832,062.69 |
| 信用减值损失(新) | -13,555,936.56 | -13,741,308.26 | -7,601,842.94 | -14,804,925.24 |
| 其他收益 | 17,978,350.74 | 11,488,896 | 4,552,561.67 | 91,827,182.93 |
| 四、营业利润 | 197,307,297.13 | 191,549,753.11 | 101,093,316.29 | 277,776,647.72 |
| 加:营业外收入 | 4,959,038.76 | 3,614,697.46 | 3,301,308.45 | 1,768,960.98 |
| 减:营业外支出 | 22,492,144.1 | 24,555,916.9 | 5,247,099.16 | 18,934,570.02 |
| 五、利润总额 | 179,774,191.79 | 170,608,533.67 | 99,147,525.58 | 260,611,038.68 |
| 减:所得税费用 | 17,798,276.25 | 27,868,385.52 | 18,513,607.11 | 34,338,337.95 |
| 六、净利润 | 161,975,915.54 | 142,740,148.15 | 80,633,918.47 | 226,272,700.73 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 161,975,915.54 | 142,740,148.15 | 80,633,918.47 | 226,272,700.73 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 191,321,355.95 | 162,719,731.21 | 91,735,483.67 | 275,596,143.87 |
| 少数股东损益 | -29,345,440.41 | -19,979,583.06 | -11,101,565.2 | -49,323,443.14 |
| 扣除非经常损益后的净利润 | 156,762,062.38 | 135,889,558.76 | 90,497,835.94 | 202,227,363.25 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.33 | 0.28 | 0.16 | 0.47 |
| (二)稀释每股收益 | 0.27 | 0.28 | 0.16 | 0.47 |
| 八、其他综合收益 | -1,751,561.64 | 607,182.97 | 161,778.27 | -4,533,779.91 |
| 归属于母公司股东的其他综合收益 | -1,751,561.64 | 607,182.97 | 161,778.27 | -4,253,464.13 |
| 九、综合收益总额 | 160,224,353.9 | 143,347,331.12 | 80,795,696.74 | 221,738,920.82 |
| 归属于母公司股东的综合收益总额 | 189,569,794.31 | 163,326,914.18 | 91,897,261.94 | 271,342,679.74 |
| 归属于少数股东的综合收益总额 | -29,345,440.41 | -19,979,583.06 | -11,101,565.2 | -49,603,758.92 |
| 公告日期 | 2025-10-31 | 2025-08-30 | 2025-04-29 | 2025-04-29 |
| 审计意见(境内) | | | | 标准无保留意见 |